Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Entrada Therapeutics, Inc.

NASDAQ: TRDA · Life Sciences · 2 alerts · CIK 1689375

Share price
$5.00Close, Nov 16
Market cap
$196M
Shares outstanding
39.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Entrada Therapeutics, Inc. filings on SEC EDGAR ↗

7:52 AM ET 8-K
Clinical Trial Data

Entrada Therapeutics Clinical Trial Data

Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.